Subcutaneous daratumumab: combining efficacy, safety & amp; convenience
IV administration of daratumumab has several issues, including a long infusion time (~7 h) and the likelihood of infusion-related toxicities. In this video, recorded at the 2018 American Society of On...
Author: VJHemOnc
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel drug combinations for Hodgkin lymphoma: more effective & amp; less toxic
While the current frontline ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen for treating advanced-stage Hodgkin lymphoma is effective with manageable side effects, ~30% of patients eve...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Moving away from chemotherapy in CLL
The drive to find treatment options for chronic lymphocytic leukemia (CLL) with lower toxicities means clinicians are relying less and less on chemotherapy. Here, William Wierda, MD, PhD, of the MD An...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Incorporating novel therapies into frontline ALL treatment
Eliminating high toxicity, invasive treatments like chemotherapy and stem cell transplant is a goal of acute lymphoblastic leukemia (ALL) research. Here, Oliver Ottmann, MD, FRCPath, of Cardiff Univer...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Drug cost vs. toxicity in MM
Hareth Nahi, MD, of the Karolinska Institutet, Stockholm, Sweden, discusses the association between drug cost and toxicity at the 23rd Congress of the European Hematology Association (EHA) 2018, held ...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Increase in Toxicity of Two Different Types for ECHELON-1 Trial
Joseph M. Connors, MD shares Increase in Toxicity of Two Different Types for ECHELON-1 Trial at AACR 2018
Author: Cancer-News
Added: 06/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 28, 2018 Category: Cancer & Oncology Source Type: podcasts
Management of immunotherapy toxicity in gynecological cancers
Physicians who are dealing with gynecological tumors have a limited experience of how to deal with the complications and toxicity associated with immunotherapy, suggests Alexandra Leary, MD, PhD, of t...
Author: VJOncology
Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Alex Lyon, Interview, BSH 2018, General, Treatment, cardiotoxicity, cardiac dysfunction, chemotherapy, disease risk, clinical trials, research, personalized medicine, cardio-oncology, cardiology, side effects, toxicity, cardioprotection, heart diseas
The field of cardio-oncology is growing on both a national and international scale. In this interview, Alex Lyon, MA, BM BCh, PhD, FRCP, from Imperial College, London, UK, talks about the formation of...
Author: VJHemOnc
Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Alex Lyon, Interview, BSH 2018, Treatment, General, Cancer, therapy, prevention, cardiovascular complications, heart failure, chemotherapy, adverse events, cardio-oncology, cardiology, side effects, toxicity
Due to the success of current treatments, patients are living longer and surviving cancer. However, certain treatments can cause cardiac complications which have a significant impact on the individual...
Author: VJHemOnc
Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Use PARP-Inhibitors Early in Therapy for Metastatic Breast Cancer | Improve Response & Delay Toxic Therapy Use
Hope S. Rugo, MD, FASCO, University of California, San Francisco shares Use PARP-Inhibitors Early in Therapy for Metastatic Breast Cancer | Improve Response & Delay Toxic Therapy Use at ASCO 2018
Author: Annual-Meeting
Added: 06/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2018 Category: Cancer & Oncology Source Type: podcasts
Could cabozantinib be a successful novel therapy for mCRPC?
Results from clinical trials determine the effectiveness, toxicity and, ultimately, the approval of novel therapies for cancer. Here, Gregory Pond, PhD, from McMaster University, Hamilton, ON, discuss...
Author: VJOncology
Added: 06/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2018 Category: Cancer & Oncology Source Type: podcasts
The current treatment landscape for penile cancer
With the involvement of so many genetic and molecular alterations in cancer, it is nearly impossible to know what pathway to target for a clinically significant outcome that also has a low toxicity le...
Author: VJOncology
Added: 06/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Guiding clinicians to recognize toxicity levels of newer immunotherapy agents
The unique side effects that accompany the use of immune checkpoint inhibitors for the treatment of cancer need to be closely monitored to ensure the highest quality of patient care. Here, Christopher...
Author: VJOncology
Added: 06/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2018 Category: Cancer & Oncology Source Type: podcasts
FDA Accepted Moxetumomab BLA Studies looking for toxicities and developments
Michelle Dawson, MD, AstraZeneca, talks about FDA Accepted Moxetumomab BLA Studies looking for toxicities and developments at ASCO 2018.
Author: Annual-Meeting
Added: 06/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Patients Tired of Toxic Chemotherapies Current data shows efficacy & maintaining quality of life
Jon Eckard, MD, TYME Inc., explains Patients Tired of Toxic Chemotherapies Current data shows efficacy & maintaining quality of life at ASCO 2018.
Author: Annual-Meeting
Added: 06/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2018 Category: Cancer & Oncology Source Type: podcasts
